Earlier this week, Manulife announced it’s changing the way it will evaluate new drugs coming to the market to help plan sponsors contain rising drug costs. This means plan members who have been prescribed certain new drugs will see their drug claims denied until Manulife evaluates the drugs and decides whether to provide reimbursement.
It could cost the federal government $3.3 billion over the next year to implement strategies that will help it cope with Canada’s aging population, says a new report by the Conference Board of Canada and the Canadian Medical Association.
NDP leader Tom Mulcair went to a Liberal-held riding today to announce he plans to work with the provinces to support universal prescription drug coverage—but the party is not classifying their promise as a national pharmacare plan.
September 2015's stats, events and opinions
Health Minister Rona Ambrose has penned a sharply-worded letter calling for the provinces and territories to co-operate with the feds to help slash the cost of prescription drugs.
Year after year, the drug plan industry studies trends in utilization and costs with an eye on what’s coming next.
There have been lots of discussions over the years about healthcare pooling—most notably increases in the cost of pooling. And the volume of the dialogue has certainly increased recently as insurers struggle with the cost/risk associated with high-cost medications.
Nine out of 10 Canadians believe they are fully covered for all costs associated with hospital stays and psychiatric treatment, finds a Sun Life survey.
A national pharmacare program wouldn’t break the bank and should in fact save taxpayers billions of dollars, a new analysis suggests.
As we know, Canadians receive most of their healthcare services through a publicly funded system administered by their province of residence and funded by the federal government. Each province and territory has an established insurance plan that delivers medically necessary hospital and physicians’ services to residents.